Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Leary A, Le Tourneau C, Varga A, Sablin MP, Gomez-Roca C, Guilbaud N, Petain A, Pavlyuk M, Delord JP.

Invest New Drugs. 2019 Aug;37(4):693-701. doi: 10.1007/s10637-018-0688-4. Epub 2018 Dec 14.

PMID:
30547316
2.

Actinic keratosis modelling in mice: A translational study.

Pillon A, Gomes B, Vandenberghe I, Cartron V, Cèbe P, Blanchet JC, Sibaud V, Guilbaud N, Audoly L, Lamant L, Kruczynski A.

PLoS One. 2017 Jun 29;12(6):e0179991. doi: 10.1371/journal.pone.0179991. eCollection 2017.

3.

The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.

Bombarde O, Larminat F, Gomez D, Frit P, Racca C, Gomes B, Guilbaud N, Calsou P.

Mol Cancer Ther. 2017 Oct;16(10):2166-2177. doi: 10.1158/1535-7163.MCT-16-0767. Epub 2017 Jun 13.

4.

Discovery bioanalysis and in vivo pharmacology as an integrated process: a case study in oncology drug discovery.

Grondin A, Pillon A, Vandenberghe I, Guilbaud N, Kruczynski A, Gomes B.

Bioanalysis. 2016 Jul;8(14):1481-98. doi: 10.4155/bio-2016-0062. Epub 2016 Jun 17.

PMID:
27314564
5.

F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

Thibault B, Clement E, Zorza G, Meignan S, Delord JP, Couderc B, Bailly C, Narducci F, Vandenberghe I, Kruczynski A, Guilbaud N, Ferré P, Annereau JP.

Cancer Lett. 2016 Jan 1;370(1):10-8. doi: 10.1016/j.canlet.2015.09.006. Epub 2015 Sep 25.

PMID:
26404751
6.

Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma.

Tierny D, Serres F, Segaoula Z, Bemelmans I, Bouchaert E, Pétain A, Brel V, Couffin S, Marchal T, Nguyen L, Thuru X, Ferré P, Guilbaud N, Gomes B.

Clin Cancer Res. 2015 Dec 1;21(23):5314-23. doi: 10.1158/1078-0432.CCR-14-3174. Epub 2015 Jul 13.

7.

Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.

Liéby-Muller F, Heudré Le Baliner Q, Grisoni S, Fournier E, Guilbaud N, Marion F.

Bioorg Med Chem Lett. 2015;25(10):2078-81. doi: 10.1016/j.bmcl.2015.03.081. Epub 2015 Apr 3.

PMID:
25872984
8.

Synthesis and biological evaluation of (-)-6-O-desmethylcryptopleurine and analogs.

Liéby-Muller F, Marion F, Schmitt P, Annereau JP, Kruczynski A, Guilbaud N, Bailly C.

Bioorg Med Chem Lett. 2015 Jan 15;25(2):184-7. doi: 10.1016/j.bmcl.2014.11.086. Epub 2014 Dec 6.

PMID:
25499434
9.

Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Leblond P, Boulet E, Bal-Mahieu C, Pillon A, Kruczynski A, Guilbaud N, Bailly C, Sarrazin T, Lartigau E, Lansiaux A, Meignan S.

Invest New Drugs. 2014 Oct;32(5):883-92. doi: 10.1007/s10637-014-0132-3. Epub 2014 Jul 11.

PMID:
25008900
10.

F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.

Kruczynski A, Pillon A, Créancier L, Vandenberghe I, Gomes B, Brel V, Fournier E, Annereau JP, Currie E, Guminski Y, Bonnet D, Bailly C, Guilbaud N.

Leukemia. 2013 Nov;27(11):2139-48. doi: 10.1038/leu.2013.108. Epub 2013 Apr 9.

PMID:
23568148
11.

CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.

Thomas-Pfaab M, Annereau JP, Munsch C, Guilbaud N, Garrido I, Paul C, Brousset P, Lamant L, Meyer N.

J Dermatol Sci. 2013 Feb;69(2):105-13. doi: 10.1016/j.jdermsci.2012.11.003. Epub 2012 Nov 10.

PMID:
23219141
12.

The nonlysosomal β-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells.

Sorli SC, Colié S, Albinet V, Dubrac A, Touriol C, Guilbaud N, Bedia C, Fabriàs G, Casas J, Ségui B, Levade T, Andrieu-Abadie N.

FASEB J. 2013 Feb;27(2):489-98. doi: 10.1096/fj.12-215152. Epub 2012 Oct 16.

PMID:
23073830
13.

Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.

Chartrain M, Riond J, Stennevin A, Vandenberghe I, Gomes B, Lamant L, Meyer N, Gairin JE, Guilbaud N, Annereau JP.

PLoS One. 2012;7(5):e36762. doi: 10.1371/journal.pone.0036762. Epub 2012 May 24.

14.

Optical imaging of disseminated leukemia models in mice with near-infrared probe conjugated to a monoclonal antibody.

Pesnel S, Pillon A, Créancier L, Lerondel S, Le Pape A, Recher C, Demur C, Guilbaud N, Kruczynski A.

PLoS One. 2012;7(1):e30690. doi: 10.1371/journal.pone.0030690. Epub 2012 Jan 27.

15.

Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.

Brel V, Annereau JP, Vispé S, Kruczynski A, Bailly C, Guilbaud N.

Biochem Pharmacol. 2011 Dec 15;82(12):1843-52. doi: 10.1016/j.bcp.2011.08.028. Epub 2011 Sep 8.

PMID:
21924246
16.

An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.

Chelouah S, Monod-Wissler C, Bailly C, Barret JM, Guilbaud N, Vispé S, Käs E.

PLoS One. 2011;6(8):e23597. doi: 10.1371/journal.pone.0023597. Epub 2011 Aug 10.

17.

99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation.

Pesnel S, Guminski Y, Pillon A, Lerondel S, Imbert T, Guilbaud N, Kruczynski A, Bailly C, Le Pape A.

Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1832-41. doi: 10.1007/s00259-011-1857-2. Epub 2011 Jun 10.

PMID:
21660624
18.

Quantitation in bioluminescence imaging by correction of tissue absorption for experimental oncology.

Pesnel S, Pillon A, Créancier L, Guilbaud N, Bailly C, Kruczynski A, Lerondel S, Le Pape A.

Mol Imaging Biol. 2011 Aug;13(4):646-52. doi: 10.1007/s11307-010-0387-9.

PMID:
20686859
19.

A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment.

Annereau JP, Brel V, Dumontet C, Guminski Y, Imbert T, Broussas M, Vispé S, Bréand S, Guilbaud N, Barret JM, Bailly C.

Leuk Res. 2010 Oct;34(10):1383-9. doi: 10.1016/j.leukres.2009.12.021. Epub 2010 Jan 22.

PMID:
20096930
20.

Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA.

Vispé S, DeVries L, Créancier L, Besse J, Bréand S, Hobson DJ, Svejstrup JQ, Annereau JP, Cussac D, Dumontet C, Guilbaud N, Barret JM, Bailly C.

Mol Cancer Ther. 2009 Oct;8(10):2780-90. doi: 10.1158/1535-7163.MCT-09-0549. Epub 2009 Oct 6.

21.

Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.

Kruczynski A, Vandenberghe I, Pillon A, Pesnel S, Goetsch L, Barret JM, Guminski Y, Le Pape A, Imbert T, Bailly C, Guilbaud N.

Invest New Drugs. 2011 Feb;29(1):9-21. doi: 10.1007/s10637-009-9328-3. Epub 2009 Sep 24.

PMID:
19777159
22.

Synthesis of conjugated spermine derivatives with 7-nitrobenzoxadiazole (NBD), rhodamine and bodipy as new fluorescent probes for the polyamine transport system.

Guminski Y, Grousseaud M, Cugnasse S, Brel V, Annereau JP, Vispé S, Guilbaud N, Barret JM, Bailly C, Imbert T.

Bioorg Med Chem Lett. 2009 May 1;19(9):2474-7. doi: 10.1016/j.bmcl.2009.03.052. Epub 2009 Mar 18.

PMID:
19332372
23.

F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.

Barret JM, Kruczynski A, Vispé S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C.

Cancer Res. 2008 Dec 1;68(23):9845-53. doi: 10.1158/0008-5472.CAN-08-2748.

24.

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T.

Cancer Res. 2006 Sep 15;66(18):9134-42.

25.

Triterpene saponins from Eryngium campestre.

Kartal M, Mitaine-Offer AC, Paululat T, Abu-Asaker M, Wagner H, Mirjolet JF, Guilbaud N, Lacaille-Dubois MA.

J Nat Prod. 2006 Jul;69(7):1105-8.

PMID:
16872157
26.

Pursaethosides A-E, triterpene saponins from Entada pursaetha.

Tapondjou AL, Miyamoto T, Mirjolet JF, Guilbaud N, Lacaille-Dubois MA.

J Nat Prod. 2005 Aug;68(8):1185-90.

PMID:
16124758
27.

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.

McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC.

Mol Cancer Ther. 2005 Apr;4(4):641-9.

28.

Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.

Le Diguarher T, Ortuno JC, Shanks D, Guilbaud N, Pierré A, Raimbaud E, Fauchère JL, Hickman JA, Tucker GC, Casara PJ.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):767-71.

PMID:
14741286
29.

Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.

Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P.

J Med Chem. 2003 Aug 28;46(18):3840-52.

PMID:
12930146
30.

Parallel liquid synthesis of N,N'-Disubstituted 3-amino azepin-2-ones as potent and specific farnesyl transferase inhibitors.

Le Diguarher T, Ortuno JC, Dorey G, Shanks D, Guilbaud N, Pierré A, Fauchère JL, Hickman JA, Tucker GC, Casara PJ.

Bioorg Med Chem. 2003 Jul 17;11(14):3193-204.

PMID:
12818682
31.

Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.

Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A.

Cancer Chemother Pharmacol. 2002 Aug;50(2):95-103. Epub 2002 Jun 25.

PMID:
12172972
32.

Acronycine derivatives as promising antitumor agents.

Guilbaud N, Léonce S, Tillequin F, Koch M, Hickman JA, Pierré A.

Anticancer Drugs. 2002 Jun;13(5):445-9. Review.

PMID:
12045455
33.

Novel bicyclic oxazolone derivatives as anti-angiogenic agents.

Perron-Sierra FM, Pierré A, Burbridge M, Guilbaud N.

Bioorg Med Chem Lett. 2002 Jun 3;12(11):1463-6.

PMID:
12031320
34.

Solid-phase synthesis of alpha-substituted 3-bisarylthio N-hydroxy propionamides as specific MMP inhibitors.

Chollet AM, Le Diguarher T, Kucharczyk N, Loynel A, Bertrand M, Tucker G, Guilbaud N, Burbridge M, Pastoureau P, Fradin A, Sabatini M, Fauchère JL, Casara P.

Bioorg Med Chem. 2002 Mar;10(3):531-44.

PMID:
11814839
35.

Description of two new human ovarian carcinoma models in nude rats suitable for laparoscopic experimentation.

Lecuru F, Guilbaud N, Agostini A, Augereau C, Vilde F, Taurelle R.

Surg Endosc. 2001 Nov;15(11):1346-52. Epub 2001 Aug 16.

PMID:
11727148
36.

Effect of pneumoperitoneum on circulating tumor DNA.

Lécuru FR, Agostini AF, Coulet FP, Robin FP, Aggerbeck MS, Jaïs JP, Guilbaud NR, Laurent-Puig PF, Blanc B.

Anticancer Res. 2001 May-Jun;21(3B):2029-32.

PMID:
11497293
37.

Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.

Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Malivet V, Chacun C, Jan M, Tillequin F, Michel S, Koch M, Pfeiffer B, Atassi G, Hickman J, Pierré A.

Clin Cancer Res. 2001 Aug;7(8):2573-80.

38.

[New approaches in experimental cancerology: in search of therapeutic models].

Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Pierré A, Hickman J.

Bull Cancer. 2001 Jan;88(1):75-84. French. No abstract available.

39.

Synthesis and cytotoxic and antitumor activity of benzo[b]pyrano[3, 2-h]acridin-7-one analogues of acronycine.

Costes N, Le Deit H, Michel S, Tillequin F, Koch M, Pfeiffer B, Renard P, Léonce S, Guilbaud N, Kraus-Berthier L, Pierré A, Atassi G.

J Med Chem. 2000 Jun 15;43(12):2395-402.

PMID:
10882366
40.

Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.

Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierré A, Atassi G.

Clin Cancer Res. 2000 Jan;6(1):297-304.

41.
42.

Synthesis of 9-O-substituted derivatives of 9-hydroxy-5, 6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10- and 11-methyl analogues with improved antitumor activity.

Guillonneau C, PierréA, Charton Y, Guilbaud N, Kraus-Berthier L, Léonce S, Michel A, Bisagni E, Atassi G.

J Med Chem. 1999 Jun 17;42(12):2191-203.

PMID:
10377224
43.

Synthesis, properties and biological evaluation of substituted furo[3,2-e] and pyrano[3,2-e]pyrido[4,3-b]indoles.

Costache E, Nguyen CH, Guilbaud N, Léonce S, Pierré A, Atassi G, Bisagni E.

Anticancer Drug Des. 1998 Jun;13(4):373-86.

PMID:
9627674
44.

Experimental antitumour activity of S 16020-2 in a panel of human tumours.

Kraus-Berthier L, Guilbaud N, Jan M, Saint-Dizier D, Rouillon MH, Burbridge MF, Pierré A, Atassi G.

Eur J Cancer. 1997 Oct;33(11):1881-7.

PMID:
9470851
45.

Eriochrome Black T, structurally related to suramin, inhibits angiogenesis and tumor growth in vivo.

Morris AD, Léonce S, Guilbaud N, Tucker GC, Pérez V, Jan M, Cordi AA, Pierré A, Atassi G.

Anticancer Drugs. 1997 Sep;8(8):746-55.

PMID:
9396618
46.

Synthesis and antitumor activity of the metformin platinum (IV) complex. Crystal structure of the tetrachloro(metformin)platinum (IV) dimethylsulfoxide solvate.

Bentefrit F, Morgant G, Viossat B, Leonce S, Guilbaud N, Pierre A, Atassi G, Nguyen HD.

J Inorg Biochem. 1997 Oct;68(1):53-9.

PMID:
9379181
47.

Antitumor activity of S 16020-2 in two orthotopic models of lung cancer.

Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Pierré A, Atassi G.

Anticancer Drugs. 1997 Mar;8(3):276-82.

PMID:
9095333
48.

Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.

Elomri A, Mitaku S, Michel S, Skaltsounis AL, Tillequin F, Koch M, Pierré A, Guilbaud N, Léonce S, Kraus-Berthier L, Rolland Y, Atassi G.

J Med Chem. 1996 Nov 22;39(24):4762-6.

PMID:
8941390
49.

Synthesis and biological evaluation of 6-(9-hydroxy-5-methyl (and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazol-1-yl)picolinic amides as new olivacine derivatives.

Landras C, Jasztold-Howorko R, Pierré A, Léonce S, Guilbaud N, Kraus-Berthier L, Guillonneau C, Rolland Y, Atassi G, Bisagni E.

Chem Pharm Bull (Tokyo). 1996 Nov;44(11):2169-72.

PMID:
8945783
50.

New purines and purine analogs as modulators of multidrug resistance.

Dhainaut A, Regnier G, Tizot A, Pierre A, Leonce S, Guilbaud N, Kraus-Berthier L, Atassi G.

J Med Chem. 1996 Sep 27;39(20):4099-108.

PMID:
8831775

Supplemental Content

Loading ...
Support Center